GMED vs HUM
Globus Medical vs Humana — AI-powered side-by-side comparison
GMED
Globus Medical
68
Buy
VS
| Metric | GMED | HUM |
|---|
| AI Score |
68
|
68
|
| Price |
$85.87
|
$389.25
|
| P/E Ratio |
21.64×
|
36.53×
|
| ROE |
11.8%
|
6.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.5%
|
13.7%
|
| Debt / Equity |
0.02×
|
0.74×
|
| Dividend Yield |
0.0%
|
0.9%
|
| RSI (14) |
70.3
|
58.2
|
| Beta |
0.954
|
0.74
|
| Expected Upside |
+0.5%
|
+9.8%
|
AI Committee View
Current Innellis committee reasoning for GMED versus HUM.
The committee scores are tied.
GMED and HUM both score 68/100.
GMED Committee View
60% agreement
5 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 70 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- RSI at 70 is in overbought territory — Technical
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
- Bollinger bandwidth of 18.3% signals elevated volatility — Risk
HUM Committee View
75% agreement
4 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth